Terumo Blood and Cell Technologies, a medical technology company, announces the appointment of Antoinette Gawin to serve as Group Managing Executive Officer (GMEO) for Terumo Corporation (TSE:4543). Terumo is redefining its internal management system to reflect rapidly expanding global operations. Gawin is the President and Chief Executive Officer of the Terumo Blood and Cell Technologies subsidiary. The appointment is effective 1 April 2022.

This announcement comes alongside Terumo’s work to enhance its competitiveness on a global scale and achieve its outlined five-year plan, referred to as GS26. Terumo has shifted its business from predominantly “in Japan for Japan” to becoming a global healthcare company. Today, about 67% of Terumo’s revenue is generated outside of Japan, driven in part by the growth of Terumo Blood and Cell Technologies under Gawin’s leadership and the steady expansion of Terumo’s Cardiac and Vascular businesses.

The newly formed GMEO position will directly shape strategy across all Terumo operating entities. Gawin is the only female and only non-Japanese leader ever to serve in this capacity. She will continue participating in Terumo’s Executive Management Meeting (EMM) as a core member.

Gawin’s vision for Terumo Blood and Cell Technologies led to its successful return to growth, achieving USD 1 billion sales in each of the last three years since she took the helm as CEO. Her vision drives the company’s aspiration to serve more patients. She led the strategic shift to blood and beyond, including entrance to the source plasma industry and double-digit growth in the cell and gene therapy sector. The strategic effort to move to blood and beyond also underpins the company’s goal to serve unmet medical needs; a recent example is the company’s collaboration with Immunicom to launch breakthrough cancer immunotherapy treatment in Europe. Gawin is helping to shape customer environments with an ecosystem of automation, services and enterprise software that improves patient access to safe and adequate blood and cells. The company’s upgraded infrastructure and delivery system are foundational and were successfully tested during COVID-19 as production rapidly flexed to meet demand shifts and support the global collection of convalescent plasma.

Find out more in the Terumo Blood and Cell Technologies blog post.